SCHEDULE 13D/A: Sinovac Biotech Faces Delisting Threat Amidst Deepening Corporate Governance Crisis, Vivo Capital Alleges Board Misconduct

Vivo Capital, an approximately 8% shareholder in Sinovac Biotech, has issued a letter to shareholders refuting the Board's claims, highlighting a severe corporate governance crisis, auditor resignation, and potential NASDAQ delisting.

Summary

• Vivo Capital, an 8% shareholder in Sinovac Biotech Ltd. (NASDAQ:SVA), sent a letter to shareholders addressing what it believes are false statements from Sinovac's Board of Directors.
• Vivo asserts that Sinovac's Board has precipitated a corporate governance crisis, eroding credibility and threatening future growth.
• Following a January 2025 Privy Council ruling on director elections, a new Board was installed, but its composition did not match the slate the Privy Council had considered.
• Multiple directors have purportedly resigned and been replaced within three months without transparency, casting substantial uncertainty over the Company's corporate governance and stability.
• Sinovac's independent auditor, Grant Thornton Zhitong Certified Public Accountants LLP, resigned on April 1, 2025, in response to the Board's statement attempting to cast doubt on the validity of past corporate actions.
• The auditor's resignation led to Sinovac's inability to timely file its annual report with the SEC, resulting in a NASDAQ non-compliance notification.
• Sinovac is required to submit a plan to regain NASDAQ compliance by July 15, 2025, and may risk being delisted if the plan is not accepted.
• Vivo supports dividend distribution but insists it must be made lawfully and equitably to the benefit of all shareholders.
• Vivo denies controlling Sinovac's Board, stating it has held only one representative on its six-seat Board since its July 2018 PIPE investment, despite holding approximately 8% of shares.
• Vivo attributes the NASDAQ trading halt in February 2019 to 1Globe's prolonged legal battle against the Company, not Vivo.
• Vivo details its critical capital contributions to Sinovac, including a $24 million injection from the PIPE investment for CoronaVac's development, a $7.5 million convertible bond to SLS in May 2020, and introducing $527 million in additional capital for CoronaVac production.
• Vivo refutes the Board's accusation of attempting to 'double-dip' on dividends, explaining its two separate investments (holding company and SLS) were distinct and essential for CoronaVac's success.
• Vivo initiated legal proceedings to protect its and all shareholders' interests due to the Board's improper actions, including threats to invalidate the PIPE transaction.
• The Board is allegedly attempting to illegally exclude Vivo and another long-term shareholder from the July 8, 2025, special shareholders meeting.
• Another major shareholder, SAIF Partners, formally requisitioned the special meeting of shareholders for July 8, 2025, to elect new directors.
• Vivo Capital intends to vote its shares in favor of SAIF Partners' proposals at the special meeting.

Sentiment

Score: 2

Explanation: The document reveals a severe corporate governance crisis, auditor resignation, NASDAQ non-compliance, and potential delisting risk, indicating significant instability and a highly negative outlook for the company.

Positives

• Vivo Capital affirms its support for fair and equitable dividend distribution for all shareholders.
• Vivo Capital's past capital contributions, including a $24 million injection from PIPE investment, a $7.5 million convertible bond, and introducing $527 million in additional capital, were critical to Sinovac's successful development and commercialization of the COVID-19 vaccine (CoronaVac).
• Vivo Capital is actively working to restore trust in Sinovac's corporate governance and ensure fair treatment for all stakeholders.

Negatives

• Sinovac's Board of Directors has made statements that Vivo Capital believes are false and misleading.
• The Board has precipitated a corporate governance crisis, threatening the company's future growth and eroding credibility with shareholders.
• The composition of the new Board installed after the January 2025 Privy Council ruling did not match the slate considered.
• Multiple directors have purportedly resigned and been replaced within three months without transparency.
• Sinovac's independent auditor, Grant Thornton Zhitong Certified Public Accountants LLP, resigned on April 1, 2025, in response to the Board's statement casting doubt on past corporate actions.
• The auditor's resignation led to Sinovac's inability to timely file its annual report with the SEC.
• Sinovac received a notification of non-compliance from NASDAQ due to the late filing.
• The Board is allegedly attempting to illegally exclude Vivo and another long-term shareholder from the July 8, 2025, special shareholders meeting.
• The Board's actions risk harming all shareholders by setting an alarming precedent regarding how it values and rewards key investors and views legal/contractual obligations.
• The Board has misleadingly asserted that Vivo intends to 'double-dip' on dividends.
• The Board has falsely claimed Vivo controlled the former Board and caused the NASDAQ trading halt.

Risks

• Potential delisting from NASDAQ if Sinovac's plan to regain compliance by July 15, 2025, is not accepted.
• Continued corporate governance instability and lack of transparency due to rapid director changes and ongoing disputes.
• Inability to attract future investors due to the Board's actions and attempts to disenfranchise long-term shareholders.
• Disruption of Sinovac's compliant operations and governance due to the current Board's actions.
• Ongoing legal battles, including Vivo's initiated legal proceedings and 1Globe's protracted lawsuit.
• Erosion of credibility with all shareholders.

Future Outlook

The document indicates a critical period for Sinovac, with an upcoming special shareholders meeting on July 8, 2025, to elect new directors and a deadline of July 15, 2025, to submit a plan to NASDAQ to regain compliance, which is crucial to avoid delisting. The ongoing corporate governance crisis and legal disputes are expected to continue impacting the company's stability and ability to attract future investment.

Management Comments

• "The Board has deceptively portrayed recent events as centering around a dispute with Vivo only. But the problem is at Sinovac's Board, not at Vivo."
• "Sinovac's Board has precipitated a corporate governance crisis that threatens the Company's future growth and has eroded its credibility with all shareholders."
• "As an investment firm, we fully expect the Company to distribute excess cash to all shareholders, including ourselves, as we are committed to fulfilling our fiduciary duties to our limited partners by seeking timely investment returns."
• "Vivo is litigating not just to protect its own interests, but the interests of all shareholders."
• "Our position is clear: all shareholders deserve to be treated fairly and equitably."
• "We urge all of our fellow shareholders to join us in helping to restore trust in the Company's governance."

Industry Context

This announcement highlights the significant corporate governance challenges that can arise in publicly traded biotechnology companies, particularly those with complex ownership structures and high-stakes product development like vaccines. The dispute underscores the importance of transparent financial reporting and stable leadership, which are critical for investor confidence in the volatile life sciences sector. The success of CoronaVac, a COVID-19 vaccine, demonstrates the high capital requirements and rapid development cycles characteristic of the industry, making stable governance even more crucial for attracting and retaining investment.

Comparison to Industry Standards

• The resignation of an independent auditor (Grant Thornton Zhitong Certified Public Accountants LLP) and subsequent NASDAQ non-compliance notification for late filing are significant deviations from standard corporate governance practices for publicly traded companies, indicating severe internal control and reporting deficiencies.
• The rapid, non-transparent replacement of multiple directors within three months, as alleged by Vivo Capital, falls far short of best practices for board stability and transparency typically observed in well-governed public companies.
• Attempts to disenfranchise long-term shareholders and exclude them from shareholder meetings, as alleged against Sinovac's Board, are contrary to fundamental shareholder rights and corporate governance principles upheld by major exchanges and regulatory bodies globally.
• The protracted legal battles and internal disputes, such as those involving 1Globe and SAIF Partners, are atypical for a company of Sinovac's stature and suggest a deeply entrenched governance crisis, unlike stable, well-managed peers in the biotech industry.

Management Changes

Corporate Governance

Legal Proceedings

• The Privy Council ruled in January 2025 that five directors had been elected in February 2018 consistent with Antiguan law.
• 1Globe launched a prolonged legal battle against Sinovac, which led to the NASDAQ trading halt in February 2019.
• Vivo Capital initiated legal proceedings to protect its interests and those of all shareholders, in response to the Board's actions, including threats to invalidate the PIPE transaction.
• 1Globe and OrbiMed have sued Vivo and another investor in Antigua.

Related Party Transactions

• Vivo Capital made a PIPE investment in Sinovac in July 2018, providing approximately $24 million to SLS for CoronaVac development.
• Vivo and its co-investor provided $7.5 million each to SLS through a convertible bond structure in May 2020.
• Vivo introduced additional investors to SLS who provided $527 million of additional capital for CoronaVac production at the end of 2020.

Stakeholder Impact

• Shareholders: Risk of disenfranchisement, potential NASDAQ delisting, erosion of credibility, uncertainty over investment value, and potential for unlawful/inequitable dividend payments.
• Investors (potential): Difficulty attracting future investors due to the Board's actions and the alarming precedent set by attempts to disenfranchise long-term shareholders.
• Employees/Management: Disruption of Sinovac's compliant operations and governance due to the current Board's actions.
• Regulatory Authorities (SEC, NASDAQ): Increased scrutiny due to non-compliance and governance issues.

Next Steps

• A Special Meeting of Shareholders will be held on July 8, 2025, to elect new directors.
• Sinovac is required to submit a plan to NASDAQ by July 15, 2025, to regain compliance and avoid delisting.
• Vivo Capital intends to vote its shares in favor of SAIF Partners' proposals at the special meeting.
• Vivo Capital will continue to engage in discussions with other shareholders regarding SAIF's proposals and the future of the Issuer.
• Vivo Capital will continue to pursue actions to influence management or the Board regarding business, capitalization, dividend policy, corporate structure, and listing status.

Key Dates

Recommendation

Keywords

Sinovac Biotech, Vivo Capital, SEC filing, Schedule 13D/A, corporate governance, shareholder dispute, NASDAQ delisting, auditor resignation, dividend policy, CoronaVac, vaccine development, biotech investment, SAIF Partners, 1Globe